The Surprising Sell Case For AstraZeneca plc

Royston Wild looks at a little-known share price catalyst for AstraZeneca plc (LON: AZN).

| More on:

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

Today I am looking at an eye-opening reason why I believe a modest product pipeline is set to constrain earnings growth at AstraZeneca (LSE: AZN) (NYSE: AZN.US).

Pipeline problems set to persist

Shares in AstraZeneca have recovered steadily from the severe weakness of last summer, rising 9% from the same period in 2012 as optimism over the company’s pipeline-development strategy has taken off. Although the company is undoubtedly heading in the right direction, I believe that AstraZeneca is set for further heavy earnings pressure before its recovery strategy kicks revenues higher.

Inflation Is Coming

Inflation is out of control, and people are running scared. But right now there’s one thing we believe Investors should avoid doing at all costs… and that’s doing nothing. That’s why we’ve put together a special report that uncovers 3 of our top UK and US share ideas to try and best hedge against inflation… and better still, we’re giving it away completely FREE today!

Click here to claim your copy now!

Under new chief executive Pascal Soriot, AstraZeneca’s future revenues prospects received a huge shot in the arm through a revised growth plan announced in March. The firm is aiming to double the number of Phase III testing asset volumes by 2016, aided by the establishment of a network of R&D centres across Europe. It is also aiming to concentrate product development towards three key areas: respiratory, inflammation and autoimmunity; cardiovascular and metabolic disease; and oncology.

Although this bodes well for earnings growth over the long term, AstraZeneca still faces massive revenues upheaval in the meantime. The company’s ambitious pipeline resuscitation plans are not ready to deliver tangible returns until 2016 at the earliest, and indeed the firm’s delayed move in restructuring its R&D operations has resulted in severe earnings weakness as critical product patents have gradually expired.

AstraZeneca saw revenues slumped 18% during January-June at constant exchange rates, to $12.62bn, a result that prompted core operating profit to dip 16% to $4.38bn. Indeed, the issue of patent loss resulted in a $500m dip in revenues in the second quarter alone. And City analysts are expected the issue to continue weighing on earnings well into the future, with a 19% and 6% drop in earnings per share forecast for 2013 and 2014 respectively.

And although the company’s product testing schedule is ticking along steadily, the results of these studies — if successful — are not expected to boost earnings for some time. In positive news the firm’s Fluenz Tetra flu drug for children received a positive assessment from the European Medicines Agency last week. The company is now awaiting European Commission approval before launch, but if given the green light, launch is not expected until 2014.

AstraZeneca is also ramping up its acquisition activity in order to supplement its organic pipeline, its most recent purchase during a busy few months being cancer immunology specialists Amplimmune in late August. But as I have said, the prospect of great earnings pressure is likely to weigh heavily while the firm’s recovery measures get into gear.

More on Investing Articles

Black father holding daughter in a field of cows
Investing Articles

Could my Stocks and Shares ISA generate £30,000 a year?

Over 2m UK citizens make some use of a Stocks and Shares ISA every year. Our writer considers if it’s…

Read more »

Surprised Black girl holding teddy bear toy on Christmas
Investing Articles

4 dividend stocks that can help me fight inflation!

I'm looking at dividend stocks to help my portfolio grow and overcome the impact of high inflation. Here are the…

Read more »

Black woman using loudspeaker to be heard
Investing Articles

2 bargain UK shares trading at less than book value

Book value is a great way to value a stock. These UK shares are trading at a price-to-book ratio of…

Read more »

Happy young female stock-picker in a cafe
Investing Articles

A FTSE AIM stock I’d add to my Stocks & Shares ISA in July

Henry Adefope highlights a FTSE AIM stock he believes could generate significant upside for his portfolio if he buys this…

Read more »

Warren Buffett at a Berkshire Hathaway AGM
Investing Articles

I’m following Warren Buffett and buying cheap dividend shares to build my wealth

I think this cheap dividend stock exhibits similar qualities to the companies Warren Buffett has in his investment portfolio.

Read more »

Smiling young man sitting in cafe and checking messages, with his laptop in front of him.
Investing Articles

2 cheap FTSE 100 shares I’m buying during the dip!

Andrew Woods explains that low P/E ratios and profitable businesses attract him to these two FTSE 100 shares.

Read more »

Hand of person putting wood cube block with word VALUE on wooden table
Investing Articles

Down 45% in a year, is now the time to buy Scottish Mortgage shares?

Jon Smith explains why Scottish Mortgage shares appear to him to be good value given their post-pandemic fall.

Read more »

Tabletop model of a bear sat on desk in front of monitors showing stock charts
Investing Articles

3 reasons why the stock market is falling today

Jon Smith explains several factors that are contributing to the stock market falling today, and his thoughts on them.

Read more »